Global Blood Plasma Market, By Type (Hyperimmune Globulin, Albumin, Factor VIII, Factor IX, Immunoglobulin and Others), Mode of Delivery (Infusion Solutions, Gels, Sprays, Biomedical Sealants), Therapeutic Indication (Immunology, Oncology, Pulmonology, Rheumatology, Transplantation, Neurology, Hematology and Other), Application (Hypogammaglobulinemia, Immunodeficiency Diseases, Hemophilia, Von Willebrand's Disease (vWD) and Others), End User (Hospitals, Clinics and Other) - Industry Trends and Forecast to 2029.
Global Blood Plasma Market Analysis and Insights
Plasma is known to possess more than 100 different proteins, such as fibrinogen, protease inhibitors, clotting factor, albumin and immunoglobulin. They play a crucial role in maintaining the blood pressure, and exchanging the minerals, including potassium and sodium.
- Global Blood Plasma Market was valued at USD 25.84 million in 2021 and is expected to reach USD 63.33 million by 2029, registering a CAGR of 10.60% during the forecast period of 2022-2029. “Hospitals” accounts for the most prominent end user segment in the respective market owing to the increase in prevalence of the chronic and infectious diseases. The market report curated by DBMR research team includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Global Blood Plasma Market Definition
Plasma refers to a straw coloured clear liquid component of the blood that is protein salt solution. Red blood cells, white blood cells, and platelets are the three types of blood cells that are suspended in the plasma. The blood plasma product have numerous advantages including the coagulation of blood, and defense, among others.
Report Scope and Market Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2022 to 2029
|
|
Base Year
|
2021
|
|
Historic Years
|
2020 (Customizable to 2019 - 2014)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Type (Hyperimmune Globulin, Albumin, Factor VIII, Factor IX, Immunoglobulin and Others), Mode of Delivery (Infusion Solutions, Gels, Sprays, Biomedical Sealants), Therapeutic Indication (Immunology, Oncology, Pulmonology, Rheumatology, Transplantation, Neurology, Hematology and Other), Application (Hypogammaglobulinemia, Immunodeficiency Diseases, Hemophilia, Von Willebrand's Disease (vWD) and Others), End User (Hospitals, Clinics and Other)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Brazil, Argentina, Peru, Rest of South America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Saudi Arabia, U.A.E, Egypt, Israel, Kuwait, South Africa, Rest of Middle East and Africa
|
|
Market Players Covered
|
Allergan (Ireland), AbbVie Inc. (US), GALDERMA (Switzerland), Evolus, Inc. (US), Revance (US), HUGEL, Inc. (South Korea), Ipsen Pharma (France), USWM, LLC. (US), Sun Pharmaceutical Industries Ltd. (India), Pfizer Inc. (US), GlaxoSmithKline plc (UK), Merz Pharma (Germany), Medytox (South Korea), Smith+Nephew (US), Sanofi (France), Novartis AG (Switzerland), Teva Pharmaceutical Industries Ltd. (Israel), LGM Pharma. (US), Lannett (US), NorthStar Rx LLC (US), and Par Pharmaceutical (US), among others
|
|
Market Opportunities
|
|
Global Blood Plasma Market Dynamics
This section deals with understanding the market drivers, opportunities, restraints and challenges. All of this is discussed in detail as below:
Drivers
-
Approval for Blood Plasma Products
The increase in number of approval for blood plasma products across the globe acts as one of the major factor driving the growth of blood plasma market. The rise in clinical studies for evaluating safety and efficiency of a wide range of therapeutic drugs have a positive impact on the market.
-
Prevalence of Blood Disorders
The rise in prevalence of blood and disorders, such as malignancies and leukemia and types of lymphoma, sickle-cell anemia and haemophilia, among others accelerate the market growth.
-
Increase In Mergers and Acquisitions
The increase in the number of mergers and acquisitions among manufacturers and research organizations to provide efficient medical care to patients and generate significant revenues by their sales options results in the expansion of the market.
Additionally, development in technology, large patient base and superior technology, increase in demand for effective therapies and surge in healthcare expenditure positively affect the blood plasma market.
Opportunities
Furthermore, research and development activities to develop advanced plasma derived product extends profitable opportunities to the market players in the forecast period of 2022 to 2029. Also, strategic manufacturing and distribution of plasma products will escalate the growth of blood plasma market.
Restraints/Challenges Global Blood Plasma Market
On the other hand, side effects caused due to use of blood plasma derivative such as dizziness, shortness in breath, allergic condition, dizziness and, fast heartbeats are expected to obstruct the market growth. The stringent regulatory policies for the approval are projected to challenge the blood plasma market in the forecast period of 2022-2029.
This blood plasma market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on blood plasma market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Patient Epidemiology Analysis
Death of more than 60,000 Americans anually have been reported due to hemorrhaging, or blood loss. Also, hemophilia A affects 1 in 5,000 male births each year in the U.S. according to the Centers for Disease Control and Prevention.
The blood plasma market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analyses of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.
COVID-19 Impact on Blood Plasma Market
The COVID-19 outbreak had a positive impact on growth of the blood plasma market. The COVID-19 pandemic stressed healthcare systems across the globe. Food and Drug Administration (FDA) issued an Emergency Use Authorization (EUA) for convalescent plasma for treating hospitalized patients with COVID-19 in August 2020. The antibodies or plasma are collected from individuals who have recovered from COVID-19 to use for the patients suffering from COVID-19.
Recent Development
- The European Blood Alliance (EBA) joined hands with the European Commission, consisting of DG CNECT, DG DIGIT and DG SANTE in May’2020. The partnership aims at building and managing an EU-wide, open-access platform that gathers data on the COVID-19 convalescent plasma therapy.
Global Blood Plasma Market
The blood plasma market is segmented on the basis of type, mode of delivery, therapeutic indication, application and end user. The growth amongst these segments will help you analyze meager growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Type
- Hyperimmune Globulin
- Albumin
- Factor Viii
- Factor Ix
- Immunoglobulin
- Others
Based on type, the blood plasma market is segmented into hyperimmune globulin, albumin, factor viii, factor ix, immunoglobulin and others.
Mode of Delivery
- Infusion Solutions
- Gels
- Sprays
- Biomedical Sealants
On the basis of mode of delivery, the blood plasma market is segmented into infusion solutions, gels, sprays and biomedical sealants.
Therapeutic Indication
- Immunology
- Oncology
- Pulmonology
- Rheumatology
- Transplantation
- Neurology
- Hematology
- Other
Based upon therapeutic indication, the blood plasma market is segmented into immunology, oncology, pulmonology, rheumatology, transplantation, neurology, hematology and other.
Application
- Hypogammaglobulinemia
- Immunodeficiency Diseases
- Hemophilia
- Von Willebrand's Disease (Vwd)
- Others
On the basis of application, the blood plasma market is segmented into hypogammaglobulinemia, immunodeficiency diseases, hemophilia, von willebrand's disease (vWD) and others.
End User
- Hospitals
- Clinics
- Other
Blood plasma market has also been segmented based on the end user into hospitals, clinics and other.
Pipeline Analysis
Allergan, AbbVie Inc., GALDERMA, Evolus, Inc., Revance, HUGEL, Inc., Ipsen Pharma,USWM, LLC., Sun Pharmaceutical Industries Ltd., Pfizer Inc., GlaxoSmithKline plc, ., among others are some of the manufacturers involved with the development of plasma products.
Blood Plasma Market Regional Analysis/Insights
The blood plasma market is analysed and market size insights and trends are provided by country, type, mode of delivery, therapeutic indication, application and end user as referenced above.
The countries covered in the blood plasma market report are U.S., Canada and Mexico in North America, Brazil, Argentina, Peru, Rest of South America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Saudi Arabia, U.A.E, Egypt, Israel, Kuwait, South Africa, Rest of Middle East and Africa.
North America dominates the blood plasma market due to the rise in the inclination towards prophylaxis treatment within the region.
Asia-Pacific is expected to witness high growth during the forecast period of 2022 to 2029 because of the early diagnosis of the diseases in countries in the region.
The country section of the report also provides individual market impacting factors and changes in regulations in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, disease epidemiology and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.
Competitive Landscape and Blood Plasma Market Share Analysis
The blood plasma market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to blood plasma market.
Some of the major players operating in the blood plasma market are
- Allergan (Ireland)
- AbbVie Inc. (US)
- GALDERMA (Switzerland)
- Evolus, Inc. (US)
- Revance (US)
- HUGEL, Inc. (South Korea)
- Ipsen Pharma (France)
- USWM, LLC. (US)
- Sun Pharmaceutical Industries Ltd. (India)
- Pfizer Inc. (US)
- GlaxoSmithKline plc (UK)
- Merz Pharma (Germany)
- Medytox (South Korea)
- Smith+Nephew (US)
- Sanofi (France)
- Novartis AG (Switzerland)
- Teva Pharmaceutical Industries Ltd. (Israel)
- LGM Pharma. (US)
- Lannett (US)
- NorthStar Rx LLC (US)
- Par Pharmaceutical (US)
SKU-